EUVIMEDEUVIMED entdecken
Crossref

Standardized Bone Health Assessment and Treatment Among Prostate Cancer Patients on Androgen Deprivation Therapy in a Large Integrated Managed Care Delivery System

Michael J Shulman iD, Brandon H Horton, Joan C Lo iD, Marilyn J Meganck, Masy K Miller, Jennifer J Park-Sigal, Andrew L Avins iD

Journal of Pharmacy Practice · 18.08.2026

DOI: 10.1177/08971900261478840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Practice, online erschienen am 18.08.2026. Verfasst von Michael J Shulman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kaiser Permanente Roseville Medical Center, Roseville, CA, USA. Die Arbeit nennt 29 Literaturangaben. Gefördert von: The Permanente Medical Group’s Delivery Science and Applied Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bone-health risk assessment and treatment among prostate-cancer patients on androgen-deprivation therapy (ADT) is often inadequately completed in clinical practice.

Objective

To determine the impact of a population-management program on bone-health risk assessment and bisphosphonate therapy among prostate-cancer patients on ADT.

Methods

We used retrospective data from a large integrated healthcare system to identify men aged 41-89 years diagnosed with prostate cancer in 2011-2024 who received ≥1 ADT dose. We compared adherence to internal guideline-recommended bone mineral density (BMD) testing, laboratory evaluation, and bisphosphonate prescriptions at baseline and during follow-up between men enrolled in the population-health program with men and men who were not enrolled (non-enrolled).

Results

Among the 9934 eligible patients, 1680 (17%) were enrolled in the program and 8254 (83%) were non-enrolled. The proportion of enrolled patients completing BMD scans within 1 year before or after ADT initiation (80.6%) was substantially higher than among non-enrolled patients (23.8%, P < 0.0001). More enrolled patients were treated with antiresorptive therapy (26.4%) than among non-enrolled patients (14.1%, P < 0.0001). Overall, enrollees were more likely to have ever received any guideline-indicated intervention (78.7% vs 27.8%, P < 0.0001). The average coverage percentage for BMD screening was 24.4% among non-enrolled patients vs 81.1% among enrolled patients ( P < 0.0001). Among antiresorptive-treatment-eligible patients, the average coverage percentage for bisphosphonate therapy was 35.5% among non-enrolled patients compared with 46.1% among enrolled patients ( P < 0.0001).

Conclusion

The population-management program significantly outperformed usual care in adherence to BMD testing, laboratory evaluation, and indicated antiresorptive osteoporosis-medication treatment among men with prostate cancer on ADT.

Schlagwörter

Stichwörter der Autor:innen

androgen deprivation therapybisphosphonatebone healthpopulation healthprostate cancer

Autor:innen und Institutionen

  • Department of Urology, Kaiser Permanente Roseville Medical Center, Roseville, CA, USA.
  • Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
  • Regional Pharmacy Clinical Services, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Leuprolide Clinic, Regional Pharmacy Clinical Services, Kaiser Permanente Northern California, Oakland, CA, USA.
  • Department of Endocrinology, Kaiser Permanente South San Francisco Medical Center, South San Francisco, CA, USA.

ORCID-Profile: Michael J Shulman, Joan C Lo, Andrew L Avins

Förderung

  • The Permanente Medical Group’s Delivery Science and Applied Research Program

Zitieren

APA

Shulman, M. J., Horton, B. H., Lo, J. C., Meganck, M. J., Miller, M. K., Park-Sigal, J. J., & Avins, A. L. (2026). Standardized Bone Health Assessment and Treatment Among Prostate Cancer Patients on Androgen Deprivation Therapy in a Large Integrated Managed Care Delivery System. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900261478840

Vancouver

Shulman MJ, Horton BH, Lo JC, Meganck MJ, Miller MK, Park-Sigal JJ, et al. Standardized Bone Health Assessment and Treatment Among Prostate Cancer Patients on Androgen Deprivation Therapy in a Large Integrated Managed Care Delivery System. Journal of Pharmacy Practice. 2026. doi:10.1177/08971900261478840

BibTeX
@article{Shulman2026,
  author = {Shulman, Michael J and Horton, Brandon H and Lo, Joan C and Meganck, Marilyn J and Miller, Masy K and Park-Sigal, Jennifer J and Avins, Andrew L},
  title = {Standardized Bone Health Assessment and Treatment Among Prostate Cancer Patients on Androgen Deprivation Therapy in a Large Integrated Managed Care Delivery System},
  journal = {Journal of Pharmacy Practice},
  year = {2026},
  doi = {10.1177/08971900261478840}
}
Kostenlos starten →